BA Research Update — August 28, 2026 (Updated)
Updated Thesis
Boeing is a global commercial aerospace, defense, and aviation-services company with a durable but currently impaired franchise built on its installed base, certification and intellectual-property barriers, airline and defense relationships, and a $715 billion backlog at June 30, 2026. Business quality is medium rather than high because these strategic assets coexist with weak profitability, including 4.7% TTM gross margin, -5.4% TTM operating margin, 2.6% TTM net margin, negative $0.27 FCF per share, and substantial execution and regulatory risk. Revenue rose 8.0% year over year in the most recent quarter, while the reported earnings-growth metric increased 27.3% in the most recent quarter, although Boeing still reported a $0.67 GAAP loss per share in 2Q 2026.
The investment grade as of this refresh is B — solid business quality. Medium-tier business, attractive-tier valuation: $296.38 blended fair value implies 43.6% upside, but negative TTM operating margin and continuing execution risk limit conviction.
Key Metrics at a Glance
- Revenue growth: +8.0% year over year
- Net margin: 2.6%
- Fair value upside: +43.6% to our estimate of $296
Current price: $206.42
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. The Boeing Company remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full BA research →](/stocks/BA)